70 related articles for article (PubMed ID: 10731972)
1. [Cytoprotective effect of amifostine in children during induction therapy according to BFM-83: report on cases].
Nowak K; Bolanowski W; Zalewska-Szewczyk B; Stolarska M; Bodalski J
Wiad Lek; 1998; 51 Suppl 4():220-6. PubMed ID: 10731972
[TBL] [Abstract][Full Text] [Related]
2. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
Reinhardt D; Hempel G; Fleischhack G; Schulz A; Boos J; Creutzig U
Klin Padiatr; 2002; 214(4):188-94. PubMed ID: 12165900
[TBL] [Abstract][Full Text] [Related]
3. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.
Creutzig U; Zimmermann M; Reinhardt D; Dworzak M; Stary J; Lehrnbecher T
J Clin Oncol; 2004 Nov; 22(21):4384-93. PubMed ID: 15514380
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of causes of death during intensive chemotherapy according to treatment protocol AML-BFM 93].
Creutzig U; Zimmermann M; Reinhardt D; Lehrnbecher T
Klin Padiatr; 2003; 215(3):151-8. PubMed ID: 12778355
[TBL] [Abstract][Full Text] [Related]
5. Cytoprotection in acute myelogenous leukemia (AML) therapy.
Grosso D; Filicko J; Garcia-Manero G; Beardell F; Brunner J; Cohn J; Ferbér A; Martinez J; Mookerjee B; Rose L; Tice D; Wagner JL; Capizzi R; Flomenberg N
Semin Oncol; 2004 Dec; 31(6 Suppl 18):67-73. PubMed ID: 15726527
[TBL] [Abstract][Full Text] [Related]
6. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
[TBL] [Abstract][Full Text] [Related]
7. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients.
Lemez P; Urbánek V
Neoplasma; 2005; 52(5):398-401. PubMed ID: 16151584
[TBL] [Abstract][Full Text] [Related]
9. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.
Creutzig U; Büchner T; Sauerland MC; Zimmermann M; Reinhardt D; Döhner H; Schlenk RF
Cancer; 2008 Feb; 112(3):562-71. PubMed ID: 18076087
[TBL] [Abstract][Full Text] [Related]
10. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
Garcia-Manero G; Faderl S; Giles F; Thomas D; Cortes J; O'Brien S; Davis J; Kantarjian HM; Estey E
Haematologica; 2002 Aug; 87(8):804-7. PubMed ID: 12161355
[TBL] [Abstract][Full Text] [Related]
12. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
[TBL] [Abstract][Full Text] [Related]
13. The results of treatment with idarubicin in childhood acute nonlymphoblastic leukemia.
Saşmaz I; Tanyeli A; Bayram I; Antmen B; Yilmaz L; Küçükosmanoğlu O; Kilinç Y
Turk J Pediatr; 2004; 46(1):32-7. PubMed ID: 15074372
[TBL] [Abstract][Full Text] [Related]
14. [Ethyol (amifostine): application trial in pediatric oncology].
Korzon M; Popadiuk S; Plata-Nazar K; Gołebiewski J; Szarszewski A; Czauderna P; Stoba C
Wiad Lek; 1998; 51 Suppl 4():215-9. PubMed ID: 10731971
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation.
Hartmann JT; von Vangerow A; Fels LM; Knop S; Stolte H; Kanz L; Bokemeyer C
Br J Cancer; 2001 Feb; 84(3):313-20. PubMed ID: 11161394
[TBL] [Abstract][Full Text] [Related]
16. [Childhood acute myeloblastic leukemias. Report of 21 cases].
Laatiri MA; Chehata S; Amouri A; Bouaouina N; Chatti S; Saad A; Ennabli S
Tunis Med; 2000 Mar; 78(3):167-71. PubMed ID: 11026819
[TBL] [Abstract][Full Text] [Related]
17. Treating childhood acute myeloid leukaemia with the AML-BFM-83 protocol: experience in a developing country.
Chan LL; Abdel-Latif ME; Ariffin WA; Ariffin H; Lin HP
Br J Haematol; 2004 Sep; 126(6):799-805. PubMed ID: 15352983
[TBL] [Abstract][Full Text] [Related]
18. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
Hołowiecki J; Grosicki S; Kyrcz-Krzemien S; Skotnicki AB; Piatkowska-Jakubas B; Warzocha K; Seferynska I; Zdziarska B
Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
[TBL] [Abstract][Full Text] [Related]
19. [Effect of amifostine on reducing acute toxicity of megachemotherapy of tumors in children].
Válková J; Stanková J; Kavan P; Kabícková E; Gajdos P; Koutecký J
Cas Lek Cesk; 2002 May; 141(10):316-9. PubMed ID: 12078585
[TBL] [Abstract][Full Text] [Related]
20. Cytoprotective effects of amifostine in the treatment of childhood malignancies.
Cetingül N; Midyat L; Kantar M; Demirağ B; Aksoylar S; Kansoy S
Pediatr Blood Cancer; 2009 Jul; 52(7):829-33. PubMed ID: 19214974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
